JPM vs MET
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MET presents a conflicted profile with a stable Piotroski F-Score of 4/9 and a current price ($78.28) trading at a significant premium to both its Graham Number ($67.77) and Intrinsic Value ($32.97). While the company exhibits strong top-line revenue growth (27.6% YoY) and an attractive forward P/E of 7.15, these are offset by a concerning decline in YoY earnings growth (-34.2%). The stock is currently in a technical transition, showing strong short-term momentum (+14.7% in 1 month) despite a bearish overall technical trend score. The valuation suggests the market is pricing in a recovery in earnings that has not yet materialized in the hard data.
Compare Another Pair
Related Comparisons
JPM vs MET: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and MetLife, Inc. (MET) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.